Compositions and methods for treating cancer with anti-cd38 immunotherapy
AssigneesLentigen Technology, Inc., The U.S.A., as represented by the Secretary, Department of Health and Human Services
InventorsDina Schneider, Rimas J. Orentas, Boro Dropulic, Dimiter S. Dimitrov, Zhongyu Zhu
Life of this patent
Estimating the term…
Abstract
Chimeric antigen receptors containing CD38 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.
Claims16
-33. (canceled)
A method of providing an anti-tumor immunity in a human subject comprising administering to the human subject an effective amount of an isolated T cell or an isolated natural killer (NK) cell, wherein the isolated T cell or the isolated NK cell comprises a vector comprising a nucleic acid molecule encoding a chimeric antigen receptor (CAR) comprising at least one extracellular antigen binding domain comprising a CD38 antigen binding domain comprising the amino acid sequence of SEQ ID NO:
- 6, 8, 10, or 22, at least one linker or spacer domain, at least one transmembrane domain, at least one intracellular signaling domain.
A method of treating or preventing cancer in a mammal, comprising administering to the mammal the CAR of claim 15, in an amount effective to treat or prevent cancer in the mammal.
-44. (canceled)
A method of treating cancer in a human subject in need thereof, the method comprising administering to the human subject a pharmaceutical composition comprising an anti-tumor effective amount of a population of T cells or NK cells, wherein the T cells or NK cells comprise a nucleic acid sequence that encodes a chimeric antigen receptor (CAR), wherein the CAR comprises at least one extracellular antigen binding domain comprising a CD38 antigen binding domain comprising the amino acid sequence of SEQ ID NO:
- 6, 8, 10 or 22, at least one linker or spacer domain, at least one transmembrane domain, at least one intracellular signaling domain, wherein the population T cells or NK cells are T cells or NK cells of the human subject having cancer.
-48. (canceled)
Dependencies are inferred from the claim text.